Drugs / LY09004
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT04572698 | Nov 2020 → Jun 2023 | wet macular degeneration | Luye Pharma Group Ltd. | Unknown | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | LY09004 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04572698 ↗ |
| Modality | Protein / enzyme biologic | “Recombinant Human Vascular Endothelial Growth Factor Receptor Antibody Fusion Protein Eye Injection” NCT04572698 ↗ |
| Route | Other | “intraocular injection” NCT04572698 ↗ |